Procter & Gamble said net sales for the quarter ended September 30, 2025 were $22.4 billion, an increase of $649 million, or 3%, and net earnings increased 20% to $4.8 billion. The company cited higher restructuring charges related to the substantial liquidation of operations in Argentina and other Enterprise Markets in the prior year period as a factor in the increase in net earnings.

1. 01

   Procter & Gamble said net sales for the quarter ended September 30, 2025 were $22.4 billion, an increase of $649 million, or 3%, and net earnings increased 20% to $4.8 billion. The company cited higher restructuring charges related to the substantial liquidation of operations in Argentina and other Enterprise Markets in the prior year period as a factor in the increase in net earnings.

2. 02

   Procter & Gamble attributed the 3% increase in quarterly net sales to higher pricing of 1%, favorable product mix of 1% and favorable foreign exchange of 1%, and said volume had a neutral impact. Excluding the impacts of acquisitions and divestitures and foreign exchange, organic sales increased 2%.

3. 03

   The company said operating cash flow on a year-to-date basis was $5.4 billion, an increase of $1.1 billion versus the prior year period, adjusted free cash flow was $4.9 billion and adjusted free cash flow productivity was 102%.

4. 04

   In a plan announced in June 2025, Procter & Gamble said it expects to incur approximately $1.5 to $2.0 billion in before-tax restructuring costs over a 2-year period and disclosed a plan for a reduction of up to 7,000 non-manufacturing overhead personnel by the end of fiscal 2027. The company and Clorox also jointly decided not to renew the Glad joint venture agreement.

Key figures

Quarter ended September 30, 2025

Revenue

$22.4B

Operating income

$5.9B

Net income

$4.8B

EPS

$1.95

Operating cash flow

$5.4B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.